25.07.2013 12:28:39
|
United Therapeutics Q2 Profit Rises - Quick Facts
(RTTNews) - Drug manufacturer United Therapeutics Corp. (UTHR), Thursday reported an increase in net income for the second quarter, mirroring higher revenues.
Net income for the quarter was $79.8 million or $1.52 per share, compared with $72.3 million or $1.34 per share, last year. Earnings before non-cash charges for the three-month period were $163.7 million or $3.11 per share.
On average, thirteen analysts polled by Thomson Reuters expected earnings per share of $1.47 for the quarter. Analysts' estimates typically exclude one-time items.
Total revenues for the tri-monthly period increased to $280.6 million, up from $225.6 million reported during the same quarter last year. Street's revenue estimate was $250.17 million.
Looking forward, the drug maker reaffirmed its full-year revenue guidance for three commercial products, Remodulin, Tyvaso and Adcirca, as the company expects related revenues to fall within a range of 5 percent above or below $1 billion for the year.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu United Therapeutics Corp.mehr Nachrichten
Analysen zu United Therapeutics Corp.mehr Analysen
Aktien in diesem Artikel
United Therapeutics Corp. | 347,40 | 0,35% |